DataMeds AI Launches Health Lives Here App Focused on GLP-1 Telehealth and Pharmacy Services

DataMeds AI (NASDAQ:MEDS) and Tollo Health launched the Health Lives Here mobile application, combining GLP-1 telehealth, pharmacy services, nutritional products and health tracking as part of a planned broader healthcare network.

Key Investor Takeaways

• DataMeds AI (NASDAQ:MEDS) and Tollo Health have launched Health Lives Here, initially targeting patients using GLP-1 receptor agonist medications.
• The app combines physician consultations, prescription management, pharmacy fulfillment, nutritional products, wearable data and AI-enabled health tools in one platform.
• DataMeds plans to establish Health Lives Here locations from Corexa Health’s network of more than 6,500 independent pharmacies, beginning with a pharmacy in Concord, North Carolina.
• The companies plan to expand the platform’s target populations to Long COVID patients in the fourth quarter of 2026 and later to cancer patients.
• Several components remain future initiatives, including expanded diagnostic testing and planned 2027 digital twin and healthcare provider network capabilities.

Why MEDS Stock Is in Focus

DataMeds AI and Tollo Health have launched the Health Lives Here mobile application as an integrated platform initially focused on GLP-1 users.

The app provides access to telemedicine consultations with licensed physicians who can evaluate patients for GLP-1 therapies and prescribe them where clinically appropriate. Corexa’s pharmacy operations can provide cash-pay access to FDA-approved branded GLP-1 medications, while patients can alternatively route prescriptions to another pharmacy.

The platform also offers products marketed through Corexa, including Tollo Health’s medical foods and dietary supplements.

Health Lives Here incorporates data from wearable devices including Apple Watch, Samsung Galaxy Watch, WHOOP and Oura Ring. Other features include an AI health coach, chatbot and tracking of sleep, activity and mood.

Marketing for the platform is being conducted through a partnership with NFL Alumni Health, which the companies intend to use to increase awareness, including among rural and underserved communities.

Why This Matters for Investors

The Health Lives Here launch brings together several parts of DataMeds’ healthcare infrastructure within a single consumer-facing platform.

Corexa provides the pharmacy component, while DataMeds’ Health IT capabilities support the technology layer. The company also plans to integrate diagnostic services from Helomics, including direct-to-consumer testing where legally permitted.

This structure may give DataMeds an opportunity to generate activity across multiple parts of its healthcare operations as patients interact with the platform. However, the announcement does not provide user targets, expected revenue, pricing economics or financial projections for Health Lives Here, leaving the commercial impact of the launch to be established.

The planned pharmacy network is another component to monitor. DataMeds intends to select participating Health Lives Here pharmacies from Corexa’s existing network of more than 6,500 independent pharmacies. The first location is in Concord, North Carolina, but the company did not specify how many locations are expected to join or provide a deployment timetable for the broader network.

The initial GLP-1 focus gives the platform a defined patient use case, while the planned addition of Long COVID and cancer populations would broaden its scope if implemented.

What to Watch Next

The next scheduled expansion is into Long COVID during the fourth quarter of 2026, followed by a planned move into services for cancer patients.

Investors can also watch the number of independent pharmacies joining Health Lives Here and the rollout of Helomics diagnostic testing through the application.

Longer-term plans for 2027 include patient digital twins combining medical records, laboratory results, wearable information and other health data, as well as a Health Lives Here provider network. These remain planned capabilities rather than currently available services.

Future disclosures on app adoption, prescription activity, participating pharmacies and revenue contribution will be important for assessing whether the platform develops into a material part of DataMeds’ business.

DataMEDS AI stock price